Faculty of Medical Sciences, Dermatology, State University of Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Faculty of Medicine, Public Health, Federal University of Minas Gerais, Belo Horizonte, MG, Brasil.
Arch Dermatol Res. 2024 Jun 1;316(6):313. doi: 10.1007/s00403-024-03053-6.
Female Pattern Hair Loss (FPHL) is a common form of non-scaring hair loss that occurs in adult women. Although several treatments have already been proposed for FPHL, only Topical Minoxidil accumulated an adequate level of evidence. This study aimed to evaluate the therapeutic response of MMP® (intradermal infiltration) of Minoxidil formulation in the frontal-parietal-vertex regions compared with the gold-standard home administration of Minoxidil 5% Capillary Solution. This self-controlled comparative study evaluated 16 FPHL patients, without treatment for at least 6 months, confirmed by trichoscopy with TrichoLAB® software. They received 4 monthly sessions of MMP® with Minoxidil 0,5% on the right side of the scalp (frontal-parietal-vertex areas), followed by occlusion with plastic film for 12 h and prescription of Minoxidil 5% Solution for home use once a day, on both scalp sides, starting 72 h after the procedure. The reassessment trichoscopy was 6 weeks after the last session and they answered a "self-assessment" questionnaire. Treated scalp areas were compared and showed both treatments, in general, were effective, with no difference between them. If they were analyzed separately by treated areas, there were signs of better response in the parietal-vertex regions with treatment by MMP® with Minoxidil, while clinical treatment indicated a better response in the other regions. When patients were divided into more and less advanced cases, a better response in parietal-vertex regions treated by MMP® with Minoxidil in less advanced patients was confirmed. MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced FPHL patients. It represents yet another resource to improve quality of life of these suffering patients.
女性型脱发（FPHL）是一种常见的非瘢痕性脱发，发生在成年女性中。尽管已经提出了几种治疗 FPHL 的方法，但只有米诺地尔外用制剂积累了足够的证据。本研究旨在评估 MMP®（皮内渗透）米诺地尔制剂在额顶-顶区的治疗反应，与金标准家庭使用 5%米诺地尔毛发生长液进行比较。这项自身对照的比较研究评估了 16 名 FPHL 患者，他们至少 6 个月没有接受治疗，通过 TrichoLAB®软件的 trichoscopy 确认。他们在头皮右侧接受 4 次每月 MMP®米诺地尔 0.5%治疗（额顶-顶区），然后用塑料膜覆盖 12 小时，并在治疗后 72 小时开始每天在家使用 5%米诺地尔溶液一次，涂抹在头皮两侧。末次治疗后 6 周进行重新评估 trichoscopy，并回答“自我评估”问卷。比较治疗头皮区域，两种治疗方法总体上均有效，无差异。如果按治疗区域分别分析，MMP®米诺地尔治疗的顶-顶区有更好的反应迹象，而临床治疗则表明其他区域的反应更好。当患者分为更严重和不太严重的病例时，在不太严重的患者中，MMP®米诺地尔治疗的顶-顶区反应更好。这为改善这些患者的生活质量提供了另一种资源。
